Issue link: https://www.e-digitaleditions.com/i/1496325
This section provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. EXTRA FOCUS Product Development This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No product endorsement or preference is intended. Inhalation April 2023 31 DPI development and manufacturing services Experic's experienced team provides customized for- mulation development and GMP manufacturing solutions at clinical- and commercial-scale for reser- voir and single-dose dry powder inhalation devices. With expertise in overcoming issues with hard-to- handle powders and generating new formulations, our dedicated team will work with you every step of the way to conquer your toughest challenges. Experic LLC US: +1 609 537-4040 www.expericservices.com A range of respiratory delivery solutions Industry pioneers Kindeva Drug Delivery and Merid- ian Medical Technologies recently combined, enhanc- ing scope and scale to create a leading CDMO focused on drug/device combination products. Consolidating more than a century of hands-on expertise, this new global organization provides a broad range of solu- tions—spanning inhalation, parenteral, transdermal and intradermal routes of administration. Whether working to develop a metered dose inhaler, dry pow- der inhaler, nebulizer, soft mist inhaler, nasal delivery system or any other respiratory delivery technology, we work with you to develop your novel drug delivery platform and bring life-changing therapies and the highest-quality products to patients worldwide. Kindeva Drug Delivery US: +1 800 643-8086 www.kindevadd.com Inhaled delivery of biologics Inhaled biomolecules: Can they be aerosolized? Will they keep their activity? Merxin's MRX004 soft mist inhaler delivers biologics, successfully and effectively, to the lungs for local and systemic action, as tested with a Dornase Alpha formulation. MRX004 deliv- ers one dose in 1.2 seconds through four steps (open, twist, inhale and close). is soft mist inhaler requires no cleaning, no maintenance, no dose handling, no battery and has a low carbon footprint. Merxin UK: +44 1553 406070 info@merxin.com www.MRX004.com